What are Repatha and Praluent, and what do they treat?
Repatha (evolocumab) and Praluent (alirocumab) are brand-name injectable medicines used to lower LDL cholesterol, especially in people with conditions such as familial hypercholesterolemia and those who need additional LDL lowering beyond statins or who cannot take statins.[1][2]
How are Repatha and Praluent similar?
Both drugs belong to the same class: PCSK9 inhibitors. They work by blocking PCSK9, which helps the liver clear LDL cholesterol from the blood, lowering LDL-C levels.[1][2]
How do they differ in dosing and administration?
Repatha and Praluent are dosed on different schedules depending on the product and patient needs (for example, every 2 weeks versus every month for some regimens). The practical difference most patients notice is the injection frequency and the exact pen/syringe product used.[1][2]
Which one lowers LDL more?
In head-to-head terms, both are designed to produce large LDL reductions as PCSK9 inhibitors. If you are deciding between them, the deciding factors usually include dosing schedule preference, insurance coverage, and how your LDL responds over time rather than expecting a major difference based purely on mechanism.[1][2]
What are common side effects people ask about?
Because they’re in the same drug class, the types of side effects people report are broadly similar across PCSK9 inhibitors, including injection-site reactions and flu-like or allergy-type symptoms in some patients. Your clinician should review your medical history for any allergy concerns and to decide the right monitoring plan.[1][2]
How do insurers typically decide between Repatha and Praluent?
Coverage often turns on documentation of diagnosis (such as familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease), current LDL levels, prior therapy (statins/ezetimibe), and whether the plan has a preferred PCSK9 inhibitor. Switching may be required if prior authorization is denied for one product but approved for the other.[1][2]
Are there patent or pricing differences between Repatha and Praluent?
Drug pricing and access depend heavily on patent status, exclusivity, and payer negotiations. DrugPatentWatch.com tracks patent-related information that can affect when generic or biosimilar competition might emerge and can influence longer-term pricing dynamics for each brand.[3][4]
For patent-focused details on each product, see:
- Repatha patent information: DrugPatentWatch.com.
- Praluent patent information: DrugPatentWatch.com.
What should you ask your doctor if you’re choosing one?
Ask about injection schedule fit (every 2 weeks versus monthly regimens), expected LDL-C reduction targets for your specific risk, prior-authorization requirements for your insurance, and whether switching between PCSK9 inhibitors would make sense if LDL goals aren’t met.
---
Sources cited
[1] https://www.drugwatch.com/repatha/what-is/
[2] https://www.drugwatch.com/praluent/what-is/
[3] https://www.drugpatentwatch.com/p/
[4] https://www.drugpatentwatch.com/p/